Business
The BioSpace team hit the ground running at the J.P. Morgan Healthcare Conference earlier this month to bring you the news from the streets of San Francisco.
FEATURED STORIES
LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked up tight. Fortunately, it wasn’t CEO Heather Turner’s first rodeo.
Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations. Initiatives like the Orphan Therapeutics Accelerator are attempting to solve what CEO Craig Martin says is not a science problem, but a math problem.
Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pharma and life science companies strengthen their leadership teams and boards of directors with this week’s appointments.
Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community, which includes Delaware, Maryland, Virginia and Washington, D.C.
The government said Petit and former Chief Operating Officer William Taylor engaged in a scheme to “fraudulently inflate” the revenue of MiMedx.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that the company will participate in the following upcoming investor conferences in December
Mesoblast Limited reported operational highlights and financial results for the first quarter ended September 30, 2019.
Teewinot Life Sciences Corporation announced Michael Luther Ph.D., Chief Executive Officer, will participate on the Future of Cannabinoid Biosynthesis Panel at the 31st Annual Piper Jaffray Healthcare Conference in New York being held from December 3rd – 5th, 2019 at the Lotte New York Palace.
Medexus Pharmaceuticals Inc. announced that it plans to host a conference call at 8:00 AM Eastern Time on Monday, December 2, 2019 to discuss the Company’s financial results for the second quarter ended September 30, 2019, as well as the Company’s corporate progress and other developments.
Patented AltuCaps® for Microencapsulation of stem cells for autoimmune and inflammatory diseases: Partnering opportunities available
Dr. Singh is renowned for her expertise in molecular science, clinical management and national health policy
La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, has left the Company to pursue other interests.